Free shipping on all orders over $ 500

Resiquimod

Cat. No. M7189

All AbMole products are for research use only, cannot be used for human consumption.

Resiquimod Structure
Synonym:

R848; S28463

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
5mg USD 32  USD32 In stock
10mg USD 48  USD48 In stock
25mg USD 88  USD88 In stock
50mg USD 128  USD128 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Resiquimod (R-848) is a agonist of Toll-like receptors 7 and 8 (TLR7/TLR8) that induces upregulation of cytokines such as TNF-α, IL-6 and IFN-α. R848 (Resiquimod) induces differential TLR7 and/or TLR8 responses in human and murine immune cells. 

R848 (Resiquimod) acts as a selective activating ligand for both TLR7 and TLR8 in humans but only TLR7 in mice. It activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway with the subsequent activation of the transcription factors NF-κB and interferon regulatory factor (IRF).

Chemical Information
Molecular Weight 314.38
Formula C17H22N4O2
CAS Number 144875-48-9
Solubility (25°C) DMSO 30 mg/mL
Ethanol 20 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Jian Ye, et al. J Immunother Cancer. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer

[2] Alain H Rook, et al. Blood. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

[3] Zhi-Xia Zhou, et al. Dev Comp Immunol. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus)

[4] Maki Yokogawa, et al. Arthritis Rheumatol. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus

[5] Francesca Brugnolo, et al. J Allergy Clin Immunol. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells

Related TLR Products
Pepinh-TRIF TFA

Pepinh-TRIF TFA blocks TIR-domain-containing adapter-inducing interferon-β (TRIF) signaling by interfering with TLR-TRIF interaction.

CAY10614

CAY10614 is a potent TLR4 antagonist. CAY10614 inhibits the lipid A-induced activation of TLR4, with an IC50 of 1.675 μM.

TLR4-IN-C34-C2-COOH

TLR4-IN-C34-C2-COO is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.

BNT411 

BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro.

Rabeximod

Rabeximod (ROB-803), an anti-rheumatic compound, impairs the differentiation and function of human pro-inflammatory dendritic cells and macrophages via downregulating TLR2 and TLR4 stimulation.

  Catalog
Abmole Inhibitor Catalog




Keywords: Resiquimod, R848; S28463 supplier, TLR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.